The Combination of Jiedu Xiaoluo Decoction with Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Accelerates Disease Remission of Non-Hodgkin Lymphoma

Yu Zhang,Lihong Yu,Ni Zhu,Hangping Ge,Jingjing Xiang,Junfa Chen,Shu Deng,Xianfu Sheng,Jianping Shen,Yan Zhou

doi:10.1155/2021/2745705

Abstract

Objective This study aimed to explore the therapeutic effects of autologous peripheral blood stem cell transplantation (APBSCT) with Jiedu Xiaoluo decoction (JDX) on non-Hodgkin lymphoma (NHL). Method B lymphoma cells A20 were used to establish nude mice-transplanted tumor model. The peripheral blood of mice was analyzed by automatic blood cell counter. Inflammatory cytokines in tumor tissues were measured by ELISA, real-time qRT-PCR, and western blotting assays. Immunohistochemical staining was employed to evaluate tumor cell growth and apoptosis. CCK8 and Transwell assays were used to detect cell viability, migration, and invasion. Cell apoptosis in vitro was evaluated with flow cytometry. Result In the in vitro co-culture system of A20 cells and hemopoietic stem cells (HSC), JDX notably inhibited the proliferation, migration, and invasion and promoted apoptosis of A20 cells compared to HSC treatment alone. In animal tumor xenografts of NHL, the combination of APBSCT with JDX significantly promoted hematopoietic reconstitution, inhibited tumorigenesis of A20 cell, promoted the inflammatory microenvironment remission, inhibited cell proliferation, and promoted apoptosis compared to APBSCT alone. Conclusion The combination of APBSCT with JDX might be an effective strategy to treat NHL through inhibiting tumorigenesis and reconstructing hematopoietic and immune microenvironment. Our finding provided a novel insight into the clinical application of Traditional Chinese Medicine (TCM) against NHL.

Highlights

Non-Hodgkin lymphoma (NHL) is a lymphoid malignancy with diverse biological and clinical behavior, including persistent painless lymphadenopathy or constitutional symptoms of other organs besides the lymphoid and hematopoietic system [1]
Jiedu Xiaoluo decoction (JDX) Management Promotes Hematopoietic Recovery after Autologous Peripheral Blood Stem Cell Transplantation (APBSCT). e treatment effect of autologous peripheral blood stem cell transplantation (APBSCT) is always restricted by delayed hematopoietic recovery during treating NHL
The results demonstrated that JDX could accelerate the recovery and mobilization of Hematopoietic stem cell (HSC) in the process of NHL treatment with APBSCT

Summary

Introduction

Non-Hodgkin lymphoma (NHL) is a lymphoid malignancy with diverse biological and clinical behavior, including persistent painless lymphadenopathy or constitutional symptoms of other organs besides the lymphoid and hematopoietic system [1]. NHL is the third most common malignant tumor, accounting for ∼10% of all types of cancers [2]. Hematopoietic stem cell (HSC) mobilization via regulating tumor microenvironment (TME) is considered as an important approach to control NHL, but mobilization agents of HSC are rare and often have strong side effects [5]. Because the effects of traditional western medicine treatment are far from satisfactory to limit the process of hematological malignancies, more attention is being paid to potential roles for Traditional Chinese Medicine (TCM) in cancer treatment [6]. Xihuang pill (XH), as a common TCM, has strong clinical effects against NHL through regulating TME [7]. Dihydrocelastrol (DHCE), a dihydro-analog of celastrol isolated from Tripterygium wilfordii (the traditional Chinese medicinal plant), exerts potent anti-tumor activity in B-cell NHL through inhibiting mammalian target of rapamycin

Methods

Results

Discussion

Conclusion